nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—DRD4—attention deficit hyperactivity disorder	0.173	0.215	CbGaD
Haloperidol—HTR1B—attention deficit hyperactivity disorder	0.153	0.191	CbGaD
Haloperidol—DRD3—attention deficit hyperactivity disorder	0.149	0.185	CbGaD
Haloperidol—DRD1—attention deficit hyperactivity disorder	0.146	0.182	CbGaD
Haloperidol—DRD2—attention deficit hyperactivity disorder	0.103	0.128	CbGaD
Haloperidol—HTR2A—attention deficit hyperactivity disorder	0.0796	0.0991	CbGaD
Haloperidol—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00344	0.0665	CbGeAlD
Haloperidol—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00183	0.0354	CbGeAlD
Haloperidol—GRIN2B—forebrain—attention deficit hyperactivity disorder	0.00182	0.0352	CbGeAlD
Haloperidol—CBR1—forebrain—attention deficit hyperactivity disorder	0.00135	0.0261	CbGeAlD
Haloperidol—CBR1—cardiovascular system—attention deficit hyperactivity disorder	0.00114	0.0221	CbGeAlD
Haloperidol—H1F0—forebrain—attention deficit hyperactivity disorder	0.00111	0.0214	CbGeAlD
Haloperidol—DRD1—forebrain—attention deficit hyperactivity disorder	0.00109	0.0211	CbGeAlD
Haloperidol—GRIN2B—nervous system—attention deficit hyperactivity disorder	0.00099	0.0191	CbGeAlD
Haloperidol—GRIN2B—central nervous system—attention deficit hyperactivity disorder	0.000953	0.0184	CbGeAlD
Haloperidol—H1F0—cardiovascular system—attention deficit hyperactivity disorder	0.000937	0.0181	CbGeAlD
Haloperidol—GRIN2B—cerebellum—attention deficit hyperactivity disorder	0.000932	0.018	CbGeAlD
Haloperidol—DRD4—brain—attention deficit hyperactivity disorder	0.000902	0.0174	CbGeAlD
Haloperidol—CBR1—midbrain—attention deficit hyperactivity disorder	0.000893	0.0173	CbGeAlD
Haloperidol—HTR1B—forebrain—attention deficit hyperactivity disorder	0.000887	0.0171	CbGeAlD
Haloperidol—HTR1D—forebrain—attention deficit hyperactivity disorder	0.000859	0.0166	CbGeAlD
Haloperidol—DRD3—nervous system—attention deficit hyperactivity disorder	0.00083	0.016	CbGeAlD
Haloperidol—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000799	0.0154	CbGeAlD
Haloperidol—HTR2B—forebrain—attention deficit hyperactivity disorder	0.000799	0.0154	CbGeAlD
Haloperidol—GRIN2B—brain—attention deficit hyperactivity disorder	0.000757	0.0146	CbGeAlD
Haloperidol—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00075	0.0145	CbGeAlD
Haloperidol—CBR1—nervous system—attention deficit hyperactivity disorder	0.000734	0.0142	CbGeAlD
Haloperidol—H1F0—midbrain—attention deficit hyperactivity disorder	0.000732	0.0141	CbGeAlD
Haloperidol—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000726	0.014	CbGeAlD
Haloperidol—DRD1—midbrain—attention deficit hyperactivity disorder	0.000723	0.014	CbGeAlD
Haloperidol—Moclobemide—MAOA—attention deficit hyperactivity disorder	0.000718	0.107	CrCbGaD
Haloperidol—CBR1—central nervous system—attention deficit hyperactivity disorder	0.000707	0.0137	CbGeAlD
Haloperidol—CBR1—cerebellum—attention deficit hyperactivity disorder	0.000691	0.0133	CbGeAlD
Haloperidol—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.000675	0.013	CbGeAlD
Haloperidol—DRD2—forebrain—attention deficit hyperactivity disorder	0.000647	0.0125	CbGeAlD
Haloperidol—KCNH2—forebrain—attention deficit hyperactivity disorder	0.000637	0.0123	CbGeAlD
Haloperidol—DRD3—brain—attention deficit hyperactivity disorder	0.000634	0.0123	CbGeAlD
Haloperidol—H1F0—nervous system—attention deficit hyperactivity disorder	0.000602	0.0116	CbGeAlD
Haloperidol—DRD1—nervous system—attention deficit hyperactivity disorder	0.000594	0.0115	CbGeAlD
Haloperidol—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000586	0.0113	CbGeAlD
Haloperidol—Sertindole—DRD4—attention deficit hyperactivity disorder	0.000585	0.0873	CrCbGaD
Haloperidol—H1F0—central nervous system—attention deficit hyperactivity disorder	0.000579	0.0112	CbGeAlD
Haloperidol—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000572	0.011	CbGeAlD
Haloperidol—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000567	0.011	CbGeAlD
Haloperidol—H1F0—cerebellum—attention deficit hyperactivity disorder	0.000566	0.0109	CbGeAlD
Haloperidol—CBR1—brain—attention deficit hyperactivity disorder	0.000561	0.0108	CbGeAlD
Haloperidol—Droperidol—DRD2—attention deficit hyperactivity disorder	0.000542	0.0808	CrCbGaD
Haloperidol—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.000539	0.0104	CbGeAlD
Haloperidol—SIGMAR1—midbrain—attention deficit hyperactivity disorder	0.000529	0.0102	CbGeAlD
Haloperidol—Sertindole—HTR1B—attention deficit hyperactivity disorder	0.000519	0.0775	CrCbGaD
Haloperidol—HRH1—forebrain—attention deficit hyperactivity disorder	0.000511	0.00986	CbGeAlD
Haloperidol—Sertindole—DRD3—attention deficit hyperactivity disorder	0.000504	0.0752	CrCbGaD
Haloperidol—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000481	0.0093	CbGeAlD
Haloperidol—Mazindol—SLC6A3—attention deficit hyperactivity disorder	0.000469	0.07	CrCbGaD
Haloperidol—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000466	0.009	CbGeAlD
Haloperidol—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000464	0.00895	CbGeAlD
Haloperidol—Sertindole—ADRA2A—attention deficit hyperactivity disorder	0.00046	0.0686	CrCbGaD
Haloperidol—H1F0—brain—attention deficit hyperactivity disorder	0.00046	0.00888	CbGeAlD
Haloperidol—DRD1—brain—attention deficit hyperactivity disorder	0.000454	0.00877	CbGeAlD
Haloperidol—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000449	0.00867	CbGeAlD
Haloperidol—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.000438	0.00846	CbGeAlD
Haloperidol—HTR2B—nervous system—attention deficit hyperactivity disorder	0.000434	0.00837	CbGeAlD
Haloperidol—DRD2—midbrain—attention deficit hyperactivity disorder	0.000427	0.00825	CbGeAlD
Haloperidol—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000427	0.00824	CbGeAlD
Haloperidol—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000421	0.00813	CbGeAlD
Haloperidol—Droperidol—HTR2A—attention deficit hyperactivity disorder	0.000418	0.0624	CrCbGaD
Haloperidol—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.000417	0.00806	CbGeAlD
Haloperidol—SIGMAR1—cerebellum—attention deficit hyperactivity disorder	0.000409	0.0079	CbGeAlD
Haloperidol—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000389	0.0075	CbGeAlD
Haloperidol—Fluspirilene—ADRA2A—attention deficit hyperactivity disorder	0.000375	0.0559	CrCbGaD
Haloperidol—HTR1B—brain—attention deficit hyperactivity disorder	0.000368	0.00711	CbGeAlD
Haloperidol—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000361	0.00697	CbGeAlD
Haloperidol—HTR1D—brain—attention deficit hyperactivity disorder	0.000356	0.00688	CbGeAlD
Haloperidol—DRD2—nervous system—attention deficit hyperactivity disorder	0.000351	0.00678	CbGeAlD
Haloperidol—Sertindole—SLC6A4—attention deficit hyperactivity disorder	0.000351	0.0524	CrCbGaD
Haloperidol—Mazindol—SLC6A4—attention deficit hyperactivity disorder	0.000351	0.0524	CrCbGaD
Haloperidol—Sertindole—DRD2—attention deficit hyperactivity disorder	0.000349	0.0521	CrCbGaD
Haloperidol—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000346	0.00668	CbGeAlD
Haloperidol—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000338	0.00653	CbGeAlD
Haloperidol—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000333	0.00643	CbGeAlD
Haloperidol—SIGMAR1—brain—attention deficit hyperactivity disorder	0.000332	0.00642	CbGeAlD
Haloperidol—HTR2B—brain—attention deficit hyperactivity disorder	0.000331	0.0064	CbGeAlD
Haloperidol—DRD2—cerebellum—attention deficit hyperactivity disorder	0.00033	0.00638	CbGeAlD
Haloperidol—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.000326	0.00629	CbGeAlD
Haloperidol—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.000292	0.00564	CbGeAlD
Haloperidol—Fluspirilene—SLC6A4—attention deficit hyperactivity disorder	0.000286	0.0427	CrCbGaD
Haloperidol—Fluspirilene—DRD2—attention deficit hyperactivity disorder	0.000284	0.0424	CrCbGaD
Haloperidol—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000282	0.00544	CbGeAlD
Haloperidol—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.000281	0.00543	CbGeAlD
Haloperidol—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00028	0.0054	CbGeAlD
Haloperidol—HRH1—nervous system—attention deficit hyperactivity disorder	0.000277	0.00535	CbGeAlD
Haloperidol—Sertindole—HTR2A—attention deficit hyperactivity disorder	0.00027	0.0402	CrCbGaD
Haloperidol—DRD2—brain—attention deficit hyperactivity disorder	0.000268	0.00518	CbGeAlD
Haloperidol—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000267	0.00516	CbGeAlD
Haloperidol—KCNH2—brain—attention deficit hyperactivity disorder	0.000264	0.00511	CbGeAlD
Haloperidol—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000236	0.00456	CbGeAlD
Haloperidol—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000232	0.00447	CbGeAlD
Haloperidol—CYP1A1—brain—attention deficit hyperactivity disorder	0.000223	0.00431	CbGeAlD
Haloperidol—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000223	0.00431	CbGeAlD
Haloperidol—Fluspirilene—HTR2A—attention deficit hyperactivity disorder	0.00022	0.0328	CrCbGaD
Haloperidol—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000218	0.00421	CbGeAlD
Haloperidol—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000214	0.00414	CbGeAlD
Haloperidol—HRH1—brain—attention deficit hyperactivity disorder	0.000212	0.00409	CbGeAlD
Haloperidol—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000211	0.00407	CbGeAlD
Haloperidol—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000206	0.00399	CbGeAlD
Haloperidol—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000203	0.00392	CbGeAlD
Haloperidol—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000198	0.00383	CbGeAlD
Haloperidol—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000185	0.00356	CbGeAlD
Haloperidol—HTR2A—brain—attention deficit hyperactivity disorder	0.000177	0.00342	CbGeAlD
Haloperidol—CYP2D6—brain—attention deficit hyperactivity disorder	0.000161	0.00311	CbGeAlD
Haloperidol—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000152	0.00293	CbGeAlD
Haloperidol—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000146	0.00282	CbGeAlD
Haloperidol—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000143	0.00276	CbGeAlD
Haloperidol—ABCB1—brain—attention deficit hyperactivity disorder	0.000116	0.00224	CbGeAlD
Haloperidol—DRD2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	1.98e-05	0.000144	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	1.98e-05	0.000144	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—TPH2—attention deficit hyperactivity disorder	1.98e-05	0.000144	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.98e-05	0.000144	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	1.97e-05	0.000143	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	1.97e-05	0.000143	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	1.96e-05	0.000143	CbGpPWpGaD
Haloperidol—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	1.95e-05	0.000142	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	1.95e-05	0.000141	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—DPYD—attention deficit hyperactivity disorder	1.95e-05	0.000141	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	1.93e-05	0.00014	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	1.93e-05	0.00014	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.92e-05	0.00014	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.9e-05	0.000138	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.84e-05	0.000134	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.83e-05	0.000133	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.81e-05	0.000131	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.8e-05	0.000131	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.8e-05	0.000131	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.79e-05	0.00013	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.78e-05	0.00013	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.78e-05	0.000129	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.77e-05	0.000129	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.77e-05	0.000129	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.76e-05	0.000128	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.75e-05	0.000127	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.75e-05	0.000127	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.74e-05	0.000127	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.74e-05	0.000127	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.74e-05	0.000126	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.74e-05	0.000126	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.74e-05	0.000126	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.74e-05	0.000126	CbGpPWpGaD
Haloperidol—EBP—Metabolism—EP300—attention deficit hyperactivity disorder	1.74e-05	0.000126	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.72e-05	0.000125	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—EP300—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.71e-05	0.000124	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.69e-05	0.000123	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.69e-05	0.000123	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.69e-05	0.000122	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.68e-05	0.000122	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.68e-05	0.000122	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.67e-05	0.000122	CbGpPWpGaD
Haloperidol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	1.66e-05	0.000121	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	1.66e-05	0.000121	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.66e-05	0.000121	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.66e-05	0.00012	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.65e-05	0.00012	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.65e-05	0.00012	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	1.64e-05	0.000119	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.63e-05	0.000119	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.63e-05	0.000118	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.61e-05	0.000117	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.61e-05	0.000117	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.6e-05	0.000116	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.58e-05	0.000115	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.58e-05	0.000115	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.58e-05	0.000115	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.58e-05	0.000115	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.58e-05	0.000114	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.57e-05	0.000114	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.57e-05	0.000114	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.57e-05	0.000114	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.56e-05	0.000113	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.55e-05	0.000113	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.55e-05	0.000113	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.55e-05	0.000113	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.55e-05	0.000113	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.53e-05	0.000111	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.53e-05	0.000111	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.52e-05	0.000111	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.52e-05	0.000111	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.51e-05	0.000109	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.5e-05	0.000109	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.5e-05	0.000109	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.48e-05	0.000108	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.48e-05	0.000108	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.46e-05	0.000106	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.46e-05	0.000106	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.45e-05	0.000105	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.44e-05	0.000105	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.43e-05	0.000104	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.43e-05	0.000104	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.43e-05	0.000104	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.42e-05	0.000103	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.42e-05	0.000103	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.41e-05	0.000102	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.4e-05	0.000101	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.4e-05	0.000101	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.39e-05	0.000101	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	1.38e-05	0.0001	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.38e-05	0.0001	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.38e-05	0.0001	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.38e-05	0.0001	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.37e-05	9.97e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.35e-05	9.79e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.35e-05	9.78e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.33e-05	9.68e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.33e-05	9.66e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.33e-05	9.66e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.31e-05	9.55e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.31e-05	9.52e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.31e-05	9.52e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.29e-05	9.4e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.28e-05	9.32e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.28e-05	9.3e-05	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	1.27e-05	9.21e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.27e-05	9.2e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.26e-05	9.17e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.26e-05	9.13e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.24e-05	9e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.24e-05	8.97e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.23e-05	8.92e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.22e-05	8.86e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.22e-05	8.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.21e-05	8.76e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.21e-05	8.76e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.2e-05	8.75e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	1.2e-05	8.73e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.2e-05	8.73e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—COMT—attention deficit hyperactivity disorder	1.2e-05	8.71e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—MAOA—attention deficit hyperactivity disorder	1.19e-05	8.64e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.19e-05	8.62e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.18e-05	8.6e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	1.18e-05	8.59e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.15e-05	8.38e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.14e-05	8.26e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.14e-05	8.25e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.14e-05	8.25e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.12e-05	8.15e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.12e-05	8.14e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.12e-05	8.12e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.1e-05	7.99e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.1e-05	7.99e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.05e-05	7.66e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.05e-05	7.62e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.04e-05	7.55e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.04e-05	7.53e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.03e-05	7.52e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.02e-05	7.39e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	1.01e-05	7.32e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	1e-05	7.27e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.99e-06	7.26e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.8e-06	7.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.64e-06	7e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.62e-06	6.99e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.61e-06	6.98e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.49e-06	6.89e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.34e-06	6.78e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.33e-06	6.78e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.32e-06	6.77e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	9.3e-06	6.75e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.3e-06	6.75e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.21e-06	6.69e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.18e-06	6.67e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.18e-06	6.67e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.16e-06	6.65e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.15e-06	6.65e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	9.14e-06	6.64e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.08e-06	6.6e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	9.07e-06	6.59e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.07e-06	6.59e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.06e-06	6.58e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.04e-06	6.57e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.99e-06	6.53e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	8.93e-06	6.48e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.84e-06	6.42e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.64e-06	6.28e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	8.55e-06	6.21e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.55e-06	6.21e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.5e-06	6.18e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	8.48e-06	6.16e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.48e-06	6.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.44e-06	6.13e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.44e-06	6.13e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.43e-06	6.12e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	8.41e-06	6.11e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	8.34e-06	6.06e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.3e-06	6.03e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.1e-06	5.88e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.96e-06	5.78e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.85e-06	5.71e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.82e-06	5.68e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.75e-06	5.63e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.43e-06	5.4e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	7.28e-06	5.29e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.25e-06	5.27e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	7.24e-06	5.26e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.24e-06	5.26e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	7.23e-06	5.25e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	7.13e-06	5.18e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.07e-06	5.14e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.9e-06	5.02e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	6.88e-06	5e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.83e-06	4.97e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	6.83e-06	4.96e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.78e-06	4.92e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.63e-06	4.81e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.62e-06	4.81e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.51e-06	4.73e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.45e-06	4.69e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.01e-06	4.37e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.9e-06	4.29e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.79e-06	4.21e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	5.63e-06	4.09e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	5.59e-06	4.06e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	5.59e-06	4.06e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.59e-06	4.06e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.51e-06	4e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	5.5e-06	4e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	5.5e-06	3.99e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	5.46e-06	3.97e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	5.42e-06	3.94e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	5.18e-06	3.76e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	5.14e-06	3.74e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—EP300—attention deficit hyperactivity disorder	5.14e-06	3.73e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	5.14e-06	3.73e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.11e-06	3.71e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	5.1e-06	3.7e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.94e-06	3.59e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.86e-06	3.53e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.76e-06	3.46e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.68e-06	3.4e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.47e-06	3.25e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.47e-06	3.25e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	4.39e-06	3.19e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	4.36e-06	3.17e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	4.32e-06	3.14e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.25e-06	3.09e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.23e-06	3.07e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.22e-06	3.06e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.16e-06	3.02e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	3.39e-06	2.46e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	3.36e-06	2.44e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.18e-06	2.31e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.13e-06	2.28e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.13e-06	2.27e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	3.12e-06	2.27e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	2.95e-06	2.14e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	2.42e-06	1.75e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	2.36e-06	1.71e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	2.22e-06	1.61e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	2.2e-06	1.6e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.88e-06	1.37e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.45e-06	1.06e-05	CbGpPWpGaD
